Skip to content

ICAAC: Nevirapine’s manufacturer examines rates of liver toxicity in key study, finds once daily dose equally safe at lower CD4 count

ICAAC: Women who shed HSV in genitals shed more HIV

ICAAC: HCV only factor associated with liver problems in patients starting HIV treatment in 2004

ICAAC: Dividing Triomune tablets may result in inadequate doses for small children; liquid best

ICAAC: TMC114 shows further promise in second POWER study

Ugandan ART programme claims to reduce sexual risk taking and the risk of HIV transmission

ICAAC: Studies look at risk factors for cell changes in anus and cervix

ICAAC: Factors unrelated to HIV or side-effects of HIV treatment major cause of illness in French cohort

ICAAC: Viral load between six to 18 months predicts longer-term success of HIV therapy